Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Previous issues

Page Path
HOME > Browse articles > Previous issues
17 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 15(1); January 2017
Prev issue Next issue
Perspective
The great rise of Intestinal Research as an international journal 3 years after its language change to English as evidenced by journal metrics
Geum Hee Jeong, Sun Huh
Intest Res 2017;15(1):1-4.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.1
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • How much progress has Blood Research made since the change of the journal title in 2013
    Sun Huh
    Blood Research.2018; 53(2): 95.     CrossRef
  • Journal metrics of Clinical and Molecular Hepatology based on the Web of Science Core Collection
    Sun Huh
    Clinical and Molecular Hepatology.2018; 24(2): 137.     CrossRef
  • Journal Metrics of Infection & Chemotherapy and Current Scholarly Journal Publication Issues
    Sun Huh
    Infection & Chemotherapy.2018; 50(3): 219.     CrossRef
  • The rapid internationalization of Annals of Pediatric Endocrinology & Metabolism as evidenced by journal metrics
    Sun Huh
    Annals of Pediatric Endocrinology & Metabolism.2017; 22(2): 77.     CrossRef
  • Clinical and Experimental Vaccine Research's promotion to internationally competitive journal evidenced by journal metrics
    Sun Huh
    Clinical and Experimental Vaccine Research.2017; 6(2): 67.     CrossRef
  • 5,431 View
  • 40 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Editorial
Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia
Eun Soo Kim
Intest Res 2017;15(1):5-6.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.5
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Vaccination strategies for Korean patients with inflammatory bowel disease
    Yoo Jin Lee, Eun Soo Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 920.     CrossRef
  • Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea
    Ji Young Chang, Sung-Ae Jung, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Ki-Nam Shim
    Intestinal Research.2018; 16(4): 599.     CrossRef
  • 4,619 View
  • 41 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Reviews
Second Korean guidelines for the management of ulcerative colitis
Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
Intest Res 2017;15(1):7-37.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.7
AbstractAbstract PDFPubReaderePub

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during exacerbation of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies, including biologics, are currently used for the management of UC. However, many challenging issues exist, which sometimes lead to differences in practice between clinicians. Therefore, the IBD study group of the Korean Association for the Study of Intestinal Diseases established the first Korean guidelines for the management of UC in 2012. This is an update of the first guidelines. It was generally made by the adaptation of several foreign guidelines as was the first edition, and encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC. The specific recommendations are presented with the quality of evidence and classification of recommendations.

Citations

Citations to this article as recorded by  
  • Comparison of Effects on 6-Thioguanine Nucleotides According to Mesalazine Formulation in Pediatric Patients with Ulcerative Colitis
    Hansol Kim, Yoon Zi Kim, Seon Young Kim, Yon Ho Choe, Mi Jin Kim
    Clinical Therapeutics.2025;[Epub]     CrossRef
  • The impact of gut microbiome enterotypes on ulcerative colitis: identifying key bacterial species and revealing species co-occurrence networks using machine learning
    Xuangao Wu, Ting Zhang, TianShun Zhang, Sunmin Park
    Gut Microbes.2024;[Epub]     CrossRef
  • Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report
    Jongbeom Shin, Ga Hyeon Baek, Boram Cha, Soo-Hyun Park, Jung-Hwan Lee, Jun-Seob Kim, Kye Sook Kwon
    Biomedicines.2024; 12(4): 800.     CrossRef
  • Anti‐inflammatory and anti‐hyperalgesic effects induced by an aqueous aged black garlic extract in rodent models of ulcerative colitis and colitis‐associated visceral pain
    Maria Loreta Libero, Elena Lucarini, Lucia Recinella, Clara Ciampi, Serena Veschi, Anna Piro, Annalisa Chiavaroli, Alessandra Acquaviva, Nilofar Nilofar, Giustino Orlando, Daniele Generali, Carla Ghelardini, Lorenzo di Cesare Mannelli, Antonio J. Montero‐
    Phytotherapy Research.2024; 38(8): 4177.     CrossRef
  • Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease
    Won Moon, Jae Jun Park
    The Korean Journal of Gastroenterology.2024; 83(6): 233.     CrossRef
  • Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors
    Sang Un Kim, Hyun Seok Lee
    The Korean Journal of Gastroenterology.2024; 84(2): 35.     CrossRef
  • Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling
    Jiryeon Jang, Sehoon Jeong
    BioChip Journal.2023; 17(4): 403.     CrossRef
  • Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
    Joo Kyung Kim, Jae Hee Cheon
    Journal of Yeungnam Medical Science.2023; 40(1): 37.     CrossRef
  • Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
    Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
    Intestinal Research.2023; 21(1): 61.     CrossRef
  • Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
    Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Low Serum Hepcidin Levels in Patients with Ulcerative Colitis – Implications for Treatment of Co-existent Iron-Deficiency Anemia
    Jagadish Ramasamy, Chinmai Jagadish, Abitha Sukumaran, Joe Varghese, Thenmozhi Mani, A. J. Joseph, Ebby George Simon, Molly Jacob
    Inflammation.2023; 46(6): 2209.     CrossRef
  • Screening for Chemical Characterization and Pharmacological Properties of Different Extracts from Nepeta italica
    Alessandra Acquaviva, Simonetta Cristina Di Simone, Nilofar, Abdelhakim Bouyahya, Gokhan Zengin, Lucia Recinella, Sheila Leone, Luigi Brunetti, Abdullahi Ibrahim Uba, Osman Guler, Maruf Balos, Ugur Cakilcioğlu, Luigi Menghini, Claudio Ferrante, Giustino
    Plants.2023; 12(15): 2785.     CrossRef
  • Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
    Intestinal Research.2023; 21(3): 339.     CrossRef
  • Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
    Intestinal Research.2023; 21(3): 353.     CrossRef
  • Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
    Soo-Young Na
    The Korean Journal of Medicine.2023; 98(5): 223.     CrossRef
  • Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis
    Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Joon Seop Lee, Sung Kook Kim, Yun Jin Jung, Sang-Bum Kang, Manasi Agrawal, Ryan Ungaro, Jean-Frederic Colombel
    Digestive Diseases and Sciences.2022; 67(7): 2866.     CrossRef
  • Cytomegalovirus in ulcerative colitis: an evidence-based approach to diagnosis and treatment
    Anuraag Jena, Shubhra Mishra, Anupam Kumar Singh, Aravind Sekar, Vishal Sharma
    Expert Review of Gastroenterology & Hepatology.2022; 16(2): 109.     CrossRef
  • Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
    Su Bum Park, Seong-Jung Kim, Jun Lee, Yoo Jin Lee, Dong Hoon Baek, Geom Seog Seo, Eun Soo Kim, Sang-Wook Kim, So Yeong Kim
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Identification of useful genes from multiple microarrays for ulcerative colitis diagnosis based on machine learning methods
    Lin Zhang, Rui Mao, Chung Tai Lau, Wai Chak Chung, Jacky C. P. Chan, Feng Liang, Chenchen Zhao, Xuan Zhang, Zhaoxiang Bian
    Scientific Reports.2022;[Epub]     CrossRef
  • Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
    Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2022; 37(6): 1140.     CrossRef
  • Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
    Soo-Kyung Park, Sang-Bum Kang, SangSoo Kim, Tae Oh Kim, Jae Myung Cha, Jong Pil Im, Chang Hwan Choi, Eun Soo Kim, Geom Seog Seo, Chang Soo Eun, Dong Soo Han, Dong Il Park
    The Korean Journal of Internal Medicine.2022; 37(5): 949.     CrossRef
  • Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
    Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
    Intestinal Research.2022; 20(4): 452.     CrossRef
  • Corticosteroid, a double-edged sword in inflammatory bowel disease management: possibility of reducing corticosteroid use through physician education
    Seulji Kim, Seong-Joon Koh
    Intestinal Research.2022; 20(4): 389.     CrossRef
  • La escala control nutricional (CONUT): una herramienta prometedora para el cribado nutricional y como predictor de severidad en la colitis ulcerosa crónica idiopática
    J.L. de-León-Rendón, R.Y. López-Pérez, N.I. Gracida-Mancilla, B. Jiménez-Bobadilla, L. Alarcón-Bernés, S. Mendoza-Ramírez, J.A. Villanueva-Herrero
    Revista de Gastroenterología de México.2021; 86(2): 110.     CrossRef
  • Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
    Jae Hee Cheon
    Journal of Rheumatic Diseases.2021; 28(1): 4.     CrossRef
  • Tumor Necrosis Factor-Alpha Inhibitor-Associated Psoriatic Alopecia in a Patient with Ulcerative Colitis: A Case Report and Review of the Literature
    Kyung Muk Jeong, Ji Yun Seo, Anna Kim, Yoo Sang Baek, Hae Jun Song, Jiehyun Jeon
    Annals of Dermatology.2021; 33(1): 82.     CrossRef
  • The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
    Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
    Intestinal Research.2021; 19(1): 62.     CrossRef
  • Comparative Study of Anti-Inflammatory Effect on DSS-Induced Ulcerative Colitis Between Novel Glycyrrhiza Variety and Official Compendia
    Sa-Haeng Kang, Young-Jae Song, Yong-Deok Jeon, Dong-Keun Kim, Jeong-Hyang Park, Ju-Ryoun Soh, Jong-Hyun Lee, Christopher Kitalong, Wonnam Kim, Hyo-Jin An, Jae-Ki Chang, Jeonghoon Lee, Jong-Sik Jin
    Applied Sciences.2021; 11(4): 1545.     CrossRef
  • McN-A-343, a muscarinic agonist, reduces inflammation and oxidative stress in an experimental model of ulcerative colitis
    Diva de Aguiar Magalhães, Jalles Arruda Batista, Stefany Guimarães Sousa, Jayro dos Santos Ferreira, Lauanda da Rocha Rodrigues, Cynthia Maria Carvalho Pereira, José Victor do Nascimento Lima, Ieda Figueira de Albuquerque, Nayonara Lanara Sousa Dutra Beze
    Life Sciences.2021; 272: 119194.     CrossRef
  • Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
    Yong Il Lee, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Gut and Liver.2021; 15(2): 232.     CrossRef
  • The controlling nutritional status score: A promising tool for nutritional screening and predicting severity in ulcerative colitis patients
    J.L. de-León-Rendón, R.Y. López-Pérez, N.I. Gracida-Mancilla, B. Jiménez-Bobadilla, L. Alarcón-Bernés, S. Mendoza-Ramírez, J.A. Villanueva-Herrero
    Revista de Gastroenterología de México (English Edition).2021; 86(2): 110.     CrossRef
  • Comparison of outcomes of cyclosporine A and infliximab for steroid‐refractory acute severe ulcerative colitis
    Eun Mi Song, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Byong Duk Ye
    Journal of Gastroenterology and Hepatology.2021; 36(9): 2463.     CrossRef
  • Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission
    Jongbeom Shin, Sung Min Kong, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim
    Gut and Liver.2021; 15(3): 401.     CrossRef
  • The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
    Byong Duk Ye, Jae Hee Cheon, Ki Hwan Song, Joo Sung Kim, Young-Ho Kim, Hyuk Yoon, Kang-Moon Lee, Sang-Bum Kang, Byung Ik Jang, Jae Jun Park, Tae Oh Kim, Dae-Wook Lee, Chee Yoong Foo, Jeong Eun Shin, Dong Il Park
    Therapeutic Advances in Gastroenterology.2021;[Epub]     CrossRef
  • Efficacy and safety of Etiasa for treatment of mild-to-moderate ulcerative colitis: A Meta-analysis
    Fang-Mei Ling, Fei-Nan Lu, Sheng-Nan Wang, Liang-Ru Zhu
    World Chinese Journal of Digestology.2021; 29(15): 880.     CrossRef
  • Draft Genome Sequence of Paraclostridium bifermentans subsp. muricolitidis Strain PAGU 1678 T , Which Exacerbates Pathosis in a Mouse Model of Ulcerative Colitis
    Ryo Kutsuna, Tohru Miyoshi-Akiyama, Junko Tomida, Yoshiaki Kawamura, Steven R. Gill
    Microbiology Resource Announcements.2021;[Epub]     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
    You Sun Kim
    Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
  • Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
    Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
    Intestinal Research.2020; 18(1): 85.     CrossRef
  • Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2020; 65(5): 1436.     CrossRef
  • Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study
    Eun Soo Kim, Hyun Seok Lee, Sung Kook Kim, Eun Young Kim, Byung Ik Jang, Kyeong Ok Kim, Chang Heon Yang, Yoo Jin Lee
    Scandinavian Journal of Gastroenterology.2020; 55(2): 163.     CrossRef
  • Multidirectional Pharma-Toxicological Study on Harpagophytum procumbens DC. ex Meisn.: An IBD-Focused Investigation
    Lucia Recinella, Annalisa Chiavaroli, Maurizio Ronci, Luigi Menghini, Luigi Brunetti, Sheila Leone, Bruno Tirillini, Paola Angelini, Stefano Covino, Roberto Venanzoni, Gokhan Zengin, Simonetta Di Simone, Maria Chiara Ciferri, Viviana di Giacomo, Amelia Ca
    Antioxidants.2020; 9(2): 168.     CrossRef
  • Pregnancy outcomes in women with inflammatory bowel disease: a 10‐year nationwide population‐based cohort study
    Han H. Lee, Jung Min Bae, Bo‐In Lee, Kang‐Moon Lee, Jeong H. Wie, Jin S. Kim, Young‐Seok Cho, Sung‐Ae Jung, Sang W. Kim, Hwang Choi, Myung‐Gyu Choi
    Alimentary Pharmacology & Therapeutics.2020; 51(9): 861.     CrossRef
  • Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study
    Youn I Choi, Yoon Jae Kim, Jun-Won Chung, Kyoung Oh Kim, Hakki Kim, Rae Woong Park, Dong Kyun Park
    JMIR Medical Informatics.2020; 8(4): e15124.     CrossRef
  • Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
    Jae Jun Park
    Journal of Rheumatic Diseases.2020; 27(3): 128.     CrossRef
  • Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease
    Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang
    Digestive Diseases.2020; 38(6): 507.     CrossRef
  • Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases
    Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
    Journal of Gastroenterology and Hepatology.2019; 34(7): 1166.     CrossRef
  • Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
    Soo-Kyung Park, Sang Hyun Park, Chang Soo Eun, Geom Seog Seo, Jong Pil Im, Tae Oh Kim, Dong-Il Park
    Intestinal Research.2019; 17(3): 349.     CrossRef
  • Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use
    Ho Suk Kang, Ja-Seol Koo, Kang Moon Lee, Dae-Bum Kim, Ji Min Lee, Yoon Jae Kim, Hyuk Yoon, Hyun Joo Jang
    World Journal of Gastroenterology.2019; 25(8): 989.     CrossRef
  • A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease
    Eun Jin Jang, Jung Eun Ha, Seul Gi Im, Myeong Gyu Kim, Hyun Soon Sohn
    Clinical Drug Investigation.2019; 39(7): 625.     CrossRef
  • Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014)
    Jung Eun Ha, Eun Jin Jang, Seul Gi Im, Hyun Soon Sohn
    Korean Journal of Clinical Pharmacy.2019; 29(2): 79.     CrossRef
  • Protective effects induced by alcoholic Phlomis fruticosa and Phlomis herba‐venti extracts in isolated rat colon: Focus on antioxidant, anti‐inflammatory, and antimicrobial activities in vitro
    Claudio Ferrante, Lucia Recinella, Maurizio Ronci, Giustino Orlando, Simonetta Di Simone, Luigi Brunetti, Annalisa Chiavaroli, Sheila Leone, Matteo Politi, Bruno Tirillini, Paola Angelini, Stefano Covino, Roberto Venanzoni, Sanda Vladimir‐Knežević, Luigi
    Phytotherapy Research.2019; 33(9): 2387.     CrossRef
  • Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
    Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
    Current Infectious Disease Reports.2018;[Epub]     CrossRef
  • Monitoring Disease Activity: How and When?
    Kang-Moon Lee
    The Korean Journal of Gastroenterology.2018; 71(2): 69.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
    You Sun Kim
    The Korean Journal of Gastroenterology.2018; 71(2): 74.     CrossRef
  • Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats
    Sehyung Pak, Sung Wook Hwang, In Kyong Shim, Sang Mun Bae, Yeon- Mi Ryu, Han-Byul Kim, Eun-ju Do, Hye-Nam Son, Eun-ji Choi, Sun-ha Park, Sang-Yeob Kim, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Nobuo Kanai, Masanori Maeda, Teruo Okano, Dong-Hoon Yang
    Scientific Reports.2018;[Epub]     CrossRef
  • Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
    Seong Ran Jeon
    Intestinal Research.2018; 16(2): 163.     CrossRef
  • Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea
    Dae Bum Kim, Kang-Moon Lee, Sang Hyoung Park, You Sun Kim, Eun Soo Kim, Jun Lee, Sung-Ae Jung, Geom Seog Seo, Ji Min Lee
    Intestinal Research.2018; 16(2): 267.     CrossRef
  • Mesenchymal Stromal Cells in the Treatment of Perianal Fistulas in Crohn'S Disease
    Jesús Castro-Poceiro, Agnès Fernández-Clotet, Julián Panés
    Immunotherapy.2018; 10(14): 1203.     CrossRef
  • Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial
    Hyuk Yoon, Dong Ho Lee, Yong-Hyun Lee, Ju-Cheol Jeong, Soo Teik Lee, Myung-Gyu Choi, Seong Woo Jeon, Ki-Nam Shim, Gwang Ho Baik, Jae Gyu Kim, Jeong Seop Moon, In-Kyung Sung, Sang Kil Lee, Poong-Lyul Rhee, Hwoon-Yong Jung, Bong Eun Lee, Hyun Soo Kim, Sang
    Gut and Liver.2018; 12(5): 516.     CrossRef
  • Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
    Jihye Park, Jae Hee Cheon
    Intestinal Research.2017; 15(3): 263.     CrossRef
  • Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
    Way-Seah Lee, Najib Azmi, Ruey-Terng Ng, Sik-Yong Ong, Sasheela Sri La Ponnampalavanar, Sanjiv Mahadeva, Ida Hilmi
    Intestinal Research.2017; 15(4): 524.     CrossRef
  • 17,177 View
  • 212 Download
  • 59 Web of Science
  • 62 Crossref
Close layer
Second Korean guidelines for the management of Crohn's disease
Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
Intest Res 2017;15(1):38-67.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.38
AbstractAbstract PDFSupplementary MaterialPubReaderePub

Crohn's disease (CD) is a chronic, progressive, and disabling inflammatory bowel disease (IBD) with an uncertain etiopathogenesis. CD can involve any site of the gastrointestinal tract from the mouth to the anus, and is associated with serious complications, such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower compared with those in Western countries, but they have been rapidly increasing during the recent decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies have been applied for the treatment of this disease. Concerning CD management, there have been substantial discrepancies among clinicians according to their personal experience and preference. To suggest recommendable approaches to the diverse problems of CD and to minimize the variations in treatment among physicians, guidelines for the management of CD were first published in 2012 by the IBD Study Group of the Korean Association for the Study of Intestinal Diseases. These are the revised guidelines based on updated evidence, accumulated since 2012. These guidelines were developed by using mainly adaptation methods, and encompass induction and maintenance treatment of CD, treatment based on disease location, treatment of CD complications, including stricture and fistula, surgical treatment, and prevention of postoperative recurrence. These are the second Korean guidelines for the management of CD and will be continuously revised as new evidence is collected.

Citations

Citations to this article as recorded by  
  • Anti–Tumor Necrosis Factor Therapy and the Risk of Gestational Diabetes in Pregnant Women With Inflammatory Bowel Disease
    Yongtai Cho, Eun-Young Choi, Ahhyung Choi, Jung Yeol Han, Byong Duk Ye, Ju Hwan Kim, Ju-Young Shin
    American Journal of Gastroenterology.2025; 120(1): 241.     CrossRef
  • Appraisal of current surgical guidelines for inflammatory bowel disease using the AGREE‐S instrument: A scoping review
    Zarnigar Mussarat Khan, Camille Ball, Dalha Saeed, Grace Tai, Shaneil Chandran, Abhishek Vashista, Simon Davey, Matthew James Lee, Steven R. Brown, Daniel Hind, Adele Elizabeth Sayers
    Colorectal Disease.2025;[Epub]     CrossRef
  • Effectiveness and Tolerability of Methotrexate Combined with Biologics in Patients with Crohn’s Disease: A Multicenter Observational Study
    Jihye Park, Jaeyoung Chun, Soo Jung Park, Jae Jun Park, Tae Il Kim, Hyuk Yoon, Jae Hee Cheon
    Digestive Diseases and Sciences.2024; 69(3): 901.     CrossRef
  • Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
    Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    Gut and Liver.2024; 18(2): 294.     CrossRef
  • Mobile monitoring system detects the disease activity pattern and shows the association with clinical outcomes in patients with newly diagnosed Crohn’s disease
    Yoo Jin Lee, Sang Gyu Kwak, Eun Soo Kim, Sung Kook Kim, Hyun Seok Lee, Yun Jin Chung, Byung Ik Jang, Kyeong Ok Kim, Jeongseok Kim, Hyeong Ho Jo, Eun Young Kim
    Scientific Reports.2024;[Epub]     CrossRef
  • Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease
    Won Moon, Jae Jun Park
    The Korean Journal of Gastroenterology.2024; 83(6): 233.     CrossRef
  • Modern treatment of perianal fistulas following Crohn’s disease
    A.L. Bejanyan, A.A. Bumbazhai, K.N. Petrenko, A.A. Sumbaev, A.V. Matinyan, I.I. Eremin
    Regenerative biotechnologies, preventive, digital and predictive medicine.2024; 1(2): 49.     CrossRef
  • Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors
    Sang Un Kim, Hyun Seok Lee
    The Korean Journal of Gastroenterology.2024; 84(2): 35.     CrossRef
  • Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
    Joo Kyung Kim, Jae Hee Cheon
    Journal of Yeungnam Medical Science.2023; 40(1): 37.     CrossRef
  • Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database
    Gi Hyeon Seo, Sung Hoon Jung
    Journal of Clinical Medicine.2023; 12(6): 2397.     CrossRef
  • Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
    Intestinal Research.2023; 21(3): 339.     CrossRef
  • Can balloon-assisted enteroscopy predict disease outcomes in patients with small-bowel Crohn’s disease?
    Ji Eun Na, Sung Noh Hong, Ji Eun Kim, Eun Ran Kim, Young-Ho Kim, Dong Kyung Chang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases
    Yong Eun Park, Hye Su Moon, Dongeun Yong, Hochan Seo, Jinho Yang, Tae-Seop Shin, Yoon-Keun Kim, Jin Ran Kim, Yoo Na Lee, Young-Ho Kim, Joo Sung Kim, Jae Hee Cheon
    Scientific Reports.2022;[Epub]     CrossRef
  • Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
    Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
    Intestinal Research.2022; 20(4): 452.     CrossRef
  • Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
    Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
    Gut and Liver.2022; 16(6): 907.     CrossRef
  • Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
    Jae Hee Cheon
    Journal of Rheumatic Diseases.2021; 28(1): 4.     CrossRef
  • The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
    Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
    Intestinal Research.2021; 19(1): 62.     CrossRef
  • Ability of Pelvic Magnetic Resonance Imaging to Predict Clinical Course of Perianal Fistula in Paediatric Crohn’s Disease Patients
    Pyeong Hwa Kim, Seo Hee Kim, Young Ah Cho, Hee Mang Yoon, Jin Seong Lee, Ah Young Jung, Seak Hee Oh, Dae Yeon Kim, Jung-Man Namgoong, Kyung Mo Kim
    Journal of Crohn's and Colitis.2021; 15(7): 1152.     CrossRef
  • Predictors of reoperation for perianal fistula in Crohn's disease
    Kwangwoo Nam, Won Beom Jung, Seung Bum Lee, Jae Seung Soh, Song Soo Yang, Seok Won Jung
    Journal of Digestive Diseases.2021; 22(6): 334.     CrossRef
  • Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
    Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
    Intestinal Research.2020; 18(1): 85.     CrossRef
  • Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2020; 65(5): 1436.     CrossRef
  • Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease
    Min Seob Kwak, Jae Myung Cha, Ji Hyun Ahn, Min Kyu Chae, Sara Jeong, Hun Hee Lee
    Medicine.2020; 99(10): e18925.     CrossRef
  • Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study
    Youn I Choi, Yoon Jae Kim, Jun-Won Chung, Kyoung Oh Kim, Hakki Kim, Rae Woong Park, Dong Kyun Park
    JMIR Medical Informatics.2020; 8(4): e15124.     CrossRef
  • Pregnancy outcomes in women with inflammatory bowel disease: a 10‐year nationwide population‐based cohort study
    Han H. Lee, Jung Min Bae, Bo‐In Lee, Kang‐Moon Lee, Jeong H. Wie, Jin S. Kim, Young‐Seok Cho, Sung‐Ae Jung, Sang W. Kim, Hwang Choi, Myung‐Gyu Choi
    Alimentary Pharmacology & Therapeutics.2020; 51(9): 861.     CrossRef
  • Effects of various genetic polymorphisms on thiopurine treatment‐associated outcomes for Korean patients with Crohn's disease
    Rihwa Choi, Mi‐Na Lee, Kyunga Kim, Sun‐Young Baek, Tae Jun Kim, Sung Noh Hong, Young‐Ho Kim, Soo‐Youn Lee
    British Journal of Clinical Pharmacology.2020; 86(11): 2302.     CrossRef
  • Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
    Jae Jun Park
    Journal of Rheumatic Diseases.2020; 27(3): 128.     CrossRef
  • Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease
    Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang
    Digestive Diseases.2020; 38(6): 507.     CrossRef
  • Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases
    Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
    Journal of Gastroenterology and Hepatology.2019; 34(7): 1166.     CrossRef
  • A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease
    Eun Jin Jang, Jung Eun Ha, Seul Gi Im, Myeong Gyu Kim, Hyun Soon Sohn
    Clinical Drug Investigation.2019; 39(7): 625.     CrossRef
  • Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
    Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
    International Journal of Colorectal Disease.2019; 34(10): 1713.     CrossRef
  • Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics
    Ji Young Chang, Jae Hee Cheon
    Digestive Diseases and Sciences.2019; 64(9): 2395.     CrossRef
  • Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014)
    Jung Eun Ha, Eun Jin Jang, Seul Gi Im, Hyun Soon Sohn
    Korean Journal of Clinical Pharmacy.2019; 29(2): 79.     CrossRef
  • Can Umbilical Cord Mesenchymal Stem Cells Treatment Be a Hope for Patients with Refractory Crohn's Disease?
    Younjoo Kim
    Gut and Liver.2018; 12(1): 5.     CrossRef
  • Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
    Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
    Current Infectious Disease Reports.2018;[Epub]     CrossRef
  • How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
    You Sun Kim
    The Korean Journal of Gastroenterology.2018; 71(2): 74.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population‐based cohort study
    J. M. Bae, H. H. Lee, B.‐I. Lee, K.‐M. Lee, S. H. Eun, M.‐L. Cho, J. S. Kim, J. M. Park, Y.‐S. Cho, I. S. Lee, S. W. Kim, H. Choi, M.‐G. Choi
    Alimentary Pharmacology & Therapeutics.2018; 48(2): 196.     CrossRef
  • Monitoring Disease Activity: How and When?
    Kang-Moon Lee
    The Korean Journal of Gastroenterology.2018; 71(2): 69.     CrossRef
  • Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats
    Sehyung Pak, Sung Wook Hwang, In Kyong Shim, Sang Mun Bae, Yeon- Mi Ryu, Han-Byul Kim, Eun-ju Do, Hye-Nam Son, Eun-ji Choi, Sun-ha Park, Sang-Yeob Kim, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Nobuo Kanai, Masanori Maeda, Teruo Okano, Dong-Hoon Yang
    Scientific Reports.2018;[Epub]     CrossRef
  • Changing treatment paradigms for the management of inflammatory bowel disease
    Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
    The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
  • Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
    Ji Min Lee, Yoon Jae Kim, Kang-Moon Lee, Hyuk Yoon, Bo-In Lee, Dae Bum Kim, Donghoon Kang
    Scandinavian Journal of Gastroenterology.2018; 53(10-11): 1280.     CrossRef
  • Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
    Jong Pil Im
    Intestinal Research.2017; 15(2): 147.     CrossRef
  • Real-world Experience of Anti–tumor Necrosis Factor Therapy for Internal Fistulas in Crohnʼs Disease
    Taku Kobayashi, Asahi Hishida, Hiroki Tanaka, Yoichiro Nuki, Shigeki Bamba, Akihiro Yamada, Toshimitsu Fujii, Shinichiro Shinzaki, Yoko Yokoyama, Atsushi Yoshida, Keiji Ozeki, Shinya Ashizuka, Noriko Kamata, Sohachi Nanjo, Kazuki Kakimoto, Misaki Nakamura
    Inflammatory Bowel Diseases.2017; 23(12): 2245.     CrossRef
  • Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
    Way-Seah Lee, Najib Azmi, Ruey-Terng Ng, Sik-Yong Ong, Sasheela Sri La Ponnampalavanar, Sanjiv Mahadeva, Ida Hilmi
    Intestinal Research.2017; 15(4): 524.     CrossRef
  • Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience
    Dai Jung, Sunghee Lee, Insook Jeong, Seak Hee Oh, Kyung Mo Kim
    Pediatric Gastroenterology, Hepatology & Nutrition.2017; 20(4): 236.     CrossRef
  • 11,776 View
  • 162 Download
  • 41 Web of Science
  • 45 Crossref
Close layer
Original Articles
Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients
Shinta Mizuno, Kosaku Nanki, Katsuyoshi Matsuoka, Keiichiro Saigusa, Keiko Ono, Mari Arai, Shinya Sugimoto, Hiroki Kiyohara, Moeko Nakashima, Kozue Takeshita, Makoto Naganuma, Wataru Suda, Masahira Hattori, Takanori Kanai
Intest Res 2017;15(1):68-74.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.68
AbstractAbstract PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/>

Recent developments in analytical techniques including next-generation sequencing have clarified the correlation between intestinal microbiota and inflammatory bowel disease. Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC) is proposed as a potential approach to resolving their dysbiosis; however, its safety and efficacy have not been confirmed. This single-arm, open-label, non-randomized study aimed to evaluate the safety and efficacy of FMT for Japanese patients with UC as the first registered clinical trial in Japan.

Methods

We enrolled 10 patients with active UC despite medical therapy. The donors were the patients' relatives and were carefully screened for infectious diseases. Fecal material was administered via colonoscopy, and the primary endpoint was the presence or absence of serious adverse events related to FMT. The secondary endpoint was a change in partial Mayo score at 12 weeks post-FMT. Scores ≤2 were considered a clinical response. Fecal samples were collected to follow changes in gut microbiota, while extracted complementary DNA were analyzed by a next-generation sequencer. We obtained written informed consent from all patients and donors. This study was approved by our Institutional Review Board and is registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN 000012814).

Results

Five patients with moderate disease and five with severe disease were enrolled. No severe adverse effects were observed. One patient achieved clinical response; however, none of the patients' microbiota diversity recovered to the donor levels.

Conclusions

The use of single FMT for UC was safe; however, we failed to show its clinical efficacy and potential to change the intestinal microbiota.

Citations

Citations to this article as recorded by  
  • Single-Donor and Pooling Strategies for Fecal Microbiota Transfer Product Preparation in Ulcerative Colitis: Systematic Review and Meta-Analysis
    Benoît Levast, Mathieu Fontaine, Stéphane Nancey, Pierre Dechelotte, Joël Doré, Philippe Lehert
    Clinical and Translational Gastroenterology.2023;[Epub]     CrossRef
  • Recipient-independent, high-accuracy FMT-response prediction and optimization in mice and humans
    Oshrit Shtossel, Sondra Turjeman, Alona Riumin, Michael R. Goldberg, Arnon Elizur, Yarin Bekor, Hadar Mor, Omry Koren, Yoram Louzoun
    Microbiome.2023;[Epub]     CrossRef
  • Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial
    Andreas Stallmach, Philip Grunert, Johannes Stallhofer, Bettina Löffler, Michael Baier, Jürgen Rödel, Michael Kiehntopf, Sophie Neugebauer, Dietmar H. Pieper, Howard Junca, Andrea Tannapfel, Ute Merkel, Ulrike Schumacher, Maria Breternitz-Gruhne, Tabitha
    Trials.2022;[Epub]     CrossRef
  • An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis
    Taobi Huang, Jinlan Xu, Maoying Wang, Ke Pu, Longquan Li, Huiyun Zhang, Yuan Liang, Weiming Sun, Yuping Wang
    Medicine.2022; 101(30): e29790.     CrossRef
  • Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
    Xiaochen Zhang, Dai Ishikawa, Toshifumi Ohkusa, Shinji Fukuda, Akihito Nagahara
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • The Effects of Multi-Donor Fecal Microbiota Transplantation Capsules Combined with Thalidomide on Hormone-Dependent Ulcerative Colitis
    Xiao-He Guo, Yan-Li Zhu, Lu Yang, Wen-Jing Li, Xue-Fang Du
    Infection and Drug Resistance.2022; Volume 15: 7495.     CrossRef
  • Fecal microbiota transplantation for ulcerative colitis
    Katsuyoshi Matsuoka
    Immunological Medicine.2021; 44(1): 30.     CrossRef
  • Bacteriotherapy for inflammatory bowel disease
    Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai
    Inflammation and Regeneration.2021;[Epub]     CrossRef
  • Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis
    Valentin Mocanu, Sabitha Rajaruban, Jerry Dang, Janice Y. Kung, Edward C. Deehan, Karen L. Madsen
    Journal of Clinical Medicine.2021; 10(5): 959.     CrossRef
  • Current status, complications and prospects of fecal microbiota transplantation therapy
    Ohara Tadashi
    Archives of Pathology and Clinical Research.2021; 5(1): 004.     CrossRef
  • Fecal Microbial Transplantation in Critically Ill Patients—Structured Review and Perspectives
    Ivana Cibulková, Veronika Řehořová, Jan Hajer, František Duška
    Biomolecules.2021; 11(10): 1459.     CrossRef
  • Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation
    Herbert L. DuPont, Zhi-Dong Jiang, Andrew W. DuPont, Netanya S. Utay
    Digestive Diseases and Sciences.2020; 65(3): 741.     CrossRef
  • Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
    Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
    Journal of Digestive Diseases.2020; 21(3): 147.     CrossRef
  • Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis
    Luciane de Fátima Caldeira, Helena H. Borba, Fernanda S. Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo, Udai P. Singh
    PLOS ONE.2020; 15(9): e0238910.     CrossRef
  • Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
    Ajit Sood, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Dina Kao, David T Rubin, Charles N Bernstein
    Crohn's & Colitis 360.2020;[Epub]     CrossRef
  • Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta‐analysis
    Hai Lan Zhao, Shu Zhen Chen, Hao Ming Xu, You Lian Zhou, Jie He, Hong Li Huang, Jing Xu, Yu Qiang Nie
    Journal of Digestive Diseases.2020; 21(10): 534.     CrossRef
  • Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians
    Ajit Sood, Vandana Midha, Harmeet Kaur, Arshdeep Singh
    Journal of Gastrointestinal Infections.2020; 10(1): 16.     CrossRef
  • Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of steroid-dependent ulcerative colitis
    Young-Seok Cho
    Intestinal Research.2019; 17(1): 6.     CrossRef
  • RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
    Jung Hoon Song, You Sun Kim
    Gut and Liver.2019; 13(1): 16.     CrossRef
  • 1) Microbiota and Gastrointestinal Diseases
    Takanori Kanai
    Nihon Naika Gakkai Zasshi.2019; 108(3): 401.     CrossRef
  • Fecal microbial transplantation
    Sonia Bouri, Ailsa Hart
    Current Opinion in Clinical Nutrition & Metabolic Care.2018; 21(5): 405.     CrossRef
  • The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis
    Yantian Cao, Bangjie Zhang, Yuanyuan Wu, Qingzhi Wang, Jie Wang, Fangfang Shen
    Gastroenterology Research and Practice.2018; 2018: 1.     CrossRef
  • Gut microbiota‐immune‐brain interactions in chemotherapy‐associated behavioral comorbidities
    Kelley R. Jordan, Brett R. Loman, Michael T. Bailey, Leah M. Pyter
    Cancer.2018; 124(20): 3990.     CrossRef
  • Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
    Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
    Current Infectious Disease Reports.2018;[Epub]     CrossRef
  • Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
    Chang Soo Eun
    Intestinal Research.2017; 15(2): 145.     CrossRef
  • Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome
    Shinta Mizuno, Tatsuhiro Masaoka, Makoto Naganuma, Taishiro Kishimoto, Momoko Kitazawa, Shunya Kurokawa, Moeko Nakashima, Kozue Takeshita, Wataru Suda, Masaru Mimura, Masahira Hattori, Takanori Kanai
    Digestion.2017; 96(1): 29.     CrossRef
  • Intestinal immune response is regulated by gut microbe
    Shun TANEMOTO, Tomohisa SUJINO, Takanori KANAI
    Japanese Journal of Clinical Immunology.2017; 40(6): 408.     CrossRef
  • 7,873 View
  • 96 Download
  • 26 Web of Science
  • 27 Crossref
Close layer
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue
Dong-Hoon Yang, Yeon-Mi Ryu, Sun-Mi Lee, Jin-Yong Jeong, Soon Man Yoon, Byong Duk Ye, Jeong-Sik Byeon, Suk-Kyun Yang, Seung-Jae Myung
Intest Res 2017;15(1):75-82.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.75
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Cyclooxygenase-2 (COX-2), 15-hydroxyprostaglandin dehydrogenase (15-PGDH), and microsomal prostaglandin E synthase-1 (mPGEs-1) regulate prostaglandin E2 (PGE2) expression and are involved in colon carcinogenesis. We investigated the expression of PGE2 and its regulating genes in sporadic human colon tumors and matched normal tissues.

Methods

Twenty colonic adenomas and 27 colonic adenocarcinomas were evaluated. COX-2 and 15-PGDH expression was quantified by real-time polymerase chain reaction. The expression of PGE2 and mPGEs-1 was measured using enzyme-linked immunosorbent assay and Western blotting, respectively.

Results

The expression of COX-2, mPGEs-1, and PGE2 did not differ between the adenomas and matched distant normal tissues. 15-PGDH expression was lower in adenomas than in the matched normal colonic tissues (P<0.001). In adenocarcinomas, mPGEs-1 and PGE2 expression was significantly higher (P<0.001 and P=0.020, respectively), and COX-2 expression did not differ from that in normal tissues (P=0.207). 15-PGDH expression was significantly lower in the normal colonic mucosa from adenocarcinoma patients than in the normal mucosa from adenoma patients (P=0.018).

Conclusions

Early inactivation of 15-PGDH, followed by activation of COX-2 and mPGEs-1, contributes to PGE2 production, leading to colon carcinogenesis. 15-PGDH might be a novel candidate marker for early detection of field defects in colon carcinogenesis.

Citations

Citations to this article as recorded by  
  • Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update
    Kyung-Soo Chun, Eun-Hee Kim, Do-Hee Kim, Na-Young Song, Wonki Kim, Hye-Kyung Na, Young-Joon Surh
    Biochemical Pharmacology.2024; 228: 116259.     CrossRef
  • Dietary intake of walnut prevented Helicobacter pylori-associated gastric cancer through rejuvenation of chronic atrophic gastritis
    Jong Min Park, Young Min Han, Yong Jin Park, Ki Baik Hahm
    Journal of Clinical Biochemistry and Nutrition.2021; 68(1): 37.     CrossRef
  • Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials
    Nagendra S. Yarla, Venkateshwar Madka, Gopal Pathuri, Chinthalapally V. Rao
    International Journal of Molecular Sciences.2020; 21(24): 9609.     CrossRef
  • A glance at…antioxidant and antiinflammatory properties of dietary cobalt
    Michael J. Glade, Michael M. Meguid
    Nutrition.2018; 46: 62.     CrossRef
  • The prostanoid pathway contains potential prognostic markers for glioblastoma
    Alexandros Theodoros Panagopoulos, Renata Nascimento Gomes, Fernando Gonçalves Almeida, Felipe da Costa Souza, José Carlos Esteves Veiga, Anna Nicolaou, Alison Colquhoun
    Prostaglandins & Other Lipid Mediators.2018; 137: 52.     CrossRef
  • 5,534 View
  • 54 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
Analysis of the clinical indications for opiate use in inflammatory bowel disease
Youran Gao, Sundas Khan, Meredith Akerman, Keith Sultan
Intest Res 2017;15(1):83-89.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.83
AbstractAbstract PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/>

Opiate use for inflammatory bowel disease (IBD), particularly high-dose (HD) use, is associated with increased mortality. It's assumed that opiate use is directly related to IBD-related complaints, although this hasn't been well defined. Our goal was to determine the indications for opiate use as a first step in developing strategies to prevent or decrease opiate use.

Methods

A retrospective cohort was formed of adults who were diagnosed with IBD and for whom outpatient evaluations from 2009 to 2014 were documented. Opiate use was defined if opiates were prescribed for a minimum of 30 days over a 365-day period. Individual chart notes were then reviewed to determine the clinical indication(s) for low-dose (LD) and HD opiate use.

Results

After a search of the electronic records of 1,109,277 patients, 3,226 patients with IBD were found. One hundred four patients were identified as opiate users, including 65 patients with Crohn's and 39 with ulcerative colitis; a total of 134 indications were available for these patients. IBD-related complaints accounted for 49.25% of the opiate indications, with abdominal pain (23.13%) being the most common. Overall, opiate use for IBD-related complaints (81.40% vs. 50.82%; P=0.0014) and abdominal pain (44.19% vs. 19.67%; P=0.0071) was more common among HD than among LD.

Conclusions

Our findings show that most IBD patients using opiates, particularly HD users, used opiates for IBD-related complaints. Future research will need to determine the degree to which these complaints are related to disease activity and to formulate non-opiate pain management strategies for patients with both active and inactive IBD.

Citations

Citations to this article as recorded by  
  • Opioid Legislation in Patients With Inflammatory Bowel Disease: A State-wide Retrospective Cohort Study
    Waseem Ahmed, Wade Billing, Timothy E Stump, Thomas Strobel, Sashidhar Sagi, Monika Fischer, Mathew Bohm
    Inflammatory Bowel Diseases.2023; 29(9): 1355.     CrossRef
  • Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project
    Samantha Baillie, Jimmy K Limdi, Ash Bassi, Aileen Fraser, Gareth Parkes, Glyn Scott, Tim Raine, Christopher A Lamb, Nicholas A Kennedy, Natalia Fumis, Melissa A Smith, Andrew Nicolaou, Holly Emms, John Wye, Anouk Lehmann, Isabel Carbery, James Goodhand,
    Frontline Gastroenterology.2023; 14(6): 497.     CrossRef
  • Abdominal pain in quiescent inflammatory bowel disease
    Matthew D. Coates, Ansh Johri, Venkata Subhash Gorrepati, Parth Maheshwari, Shannon Dalessio, Vonn Walter, August Stuart, Walter Koltun, Nana Bernasko, Andrew Tinsley, Emmanuelle D. Williams, Kofi Clarke
    International Journal of Colorectal Disease.2021; 36(1): 93.     CrossRef
  • High-Dose Opioid Use Among Veterans with Unexplained Gastrointestinal Symptoms Versus Structural Gastrointestinal Diagnoses
    Salva N. Balbale, Lishan Cao, Itishree Trivedi, Jonah J. Stulberg, Katie J. Suda, Walid F. Gellad, Charlesnika T. Evans, Bruce L. Lambert, Neil Jordan, Laurie A. Keefer
    Digestive Diseases and Sciences.2021; 66(11): 3938.     CrossRef
  • Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    Blake Niccum, Oluwatoba Moninuola, Kaia Miller, Hamed Khalili
    Clinical Gastroenterology and Hepatology.2021; 19(5): 895.     CrossRef
  • Pain in Inflammatory Bowel Disease Is Not Improved During Hospitalization: The Impact of Opioids on Pain and Healthcare Utilization
    Sameer K. Berry, Will Takakura, Catherine Bresee, Gil Y. Melmed
    Digestive Diseases and Sciences.2020; 65(6): 1777.     CrossRef
  • Predictors of mortality in inflammatory bowel disease patients treated for pneumonia
    Offir Ukashi, Yifatch Barash, Michael J. Segel, Bella Ungar, Shelly Soffer, Shomron Ben-Horin, Eyal Klang, Uri Kopylov
    Therapeutic Advances in Gastroenterology.2020;[Epub]     CrossRef
  • Integrated Psychological Care is Needed, Welcomed and Effective in Ambulatory Inflammatory Bowel Disease Management: Evaluation of a New Initiative
    Taryn Lores, Charlotte Goess, Antonina Mikocka-Walus, Kathryn L Collins, Anne L J Burke, Anna Chur-Hansen, Paul Delfabbro, Jane M Andrews
    Journal of Crohn's and Colitis.2019; 13(7): 819.     CrossRef
  • 5,942 View
  • 48 Download
  • 8 Web of Science
  • 8 Crossref
Close layer
Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases
Naoki Minami, Minoru Matsuura, Yorimitsu Koshikawa, Satoshi Yamada, Yusuke Honzawa, Shuji Yamamoto, Hiroshi Nakase
Intest Res 2017;15(1):90-96.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.90
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Our physicians work to expand the possibilities to treat female patients with inflammatory bowel disease (IBD) who wish to become pregnant. Although many drugs, including 5-aminosalicylate (5-ASA), corticosteroids, immunomodulators, and biologics, are used safely during pregnancy, few reports have described the therapeutic regimen throughout pregnancy and the management of patients who relapse during pregnancy precisely. The aim of this study was to assess the management of patients with IBD during pregnancy.

Methods

We identified 19 patients (five with Crohn's disease and 14 with ulcerative colitis [UC]) who became pregnant with a total of 23 pregnancies between May 2005 and May 2015 by reviewing the medical records of Kyoto University Hospital. The following data were collected: the maternal variables, the IBD treatment type, the disease activity, the pregnancy outcome, and the mode of delivery.

Results

Among the 19 patients, 18 had become pregnant after being diagnosed with IBD, while one had developed UC newly after pregnancy. Throughout the gestation, all patients were treated with probiotics, 5-ASA, prednisolone, cytapheresis, or infliximab. The relapse rate during pregnancy was 21.7% (5/23 cases). The five patients who experienced a relapse were able to pursue their pregnancy after intensification of their treatments. There were no adverse fetal or neonatal problems, except in one case that required an emergency Caesarean section because of placental dysfunction and in which a very low-birth-weight infant was born preterm.

Conclusions

Our present data confirmed that even if the disease flares up during pregnancy, good pregnancy outcomes can be achieved with an optimal intensification of the patient's treatment.

Citations

Citations to this article as recorded by  
  • The pregnancy outcome and drug usage during pregnancy among Taiwanese inflammatory bowel disease patients
    Chen‐Wang Chang, Shu‐Chen Wei, Jen‐Wei Chou, Tien‐Yu Huang, Chia‐Jung Kuo, Wen‐Hung Hsu, Chen‐Shuan Chung, Tzu‐Chi Hsu, Wei‐Chen Lin, Ming‐Jen Chen, Horng‐Yuan Wang
    Advances in Digestive Medicine.2023; 10(4): 226.     CrossRef
  • Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
    N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
    Drugs.2020; 80(16): 1699.     CrossRef
  • 5,349 View
  • 78 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India
Parnita Harsh, Vipin Gupta, Saurabh Kedia, Sawan Bopanna, Sucharita Pilli, Surendernath, Govind Kumar Makharia, Vineet Ahuja
Intest Res 2017;15(1):97-102.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.97
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Patients with inflammatory bowel disease (IBD) often require immunosuppressive therapy and blood transfusions and therefore are at a high risk of contracting infections due to hepatitis B (HBV) and hepatitis C (HCV) and human immunodeficiency virus (HIV). In the present study, we assessed the prevalence of these infections in patients with IBD.

Methods

This retrospective study included 908 consecutive patients with IBD (ulcerative colitis [UC], n=581; Crohn's disease [CD], n=327) who were receiving care at a tertiary care center. Ninety-five patients with intestinal tuberculosis (ITB) were recruited as disease controls. Prospectively maintained patient databases were reviewed for the prevalence of HBV surface antigen, anti-HCV antibodies, and HIV (enzyme-linked immunosorbent assay method). HCV RNA was examined in patients who tested positive for anti-HCV antibodies. Prevalence data of the study were compared with that of the general Indian population (HBV, 3.7%; HCV, 1%; HIV, 0.3%).

Results

The prevalence of HBV, HCV, and HIV was 2.4%, 1.4%, and 0.1%, respectively, in the 908 patients with IBD. Among the 581 patients with UC, 2.2% (12/541) had HBV, 1.7% (9/517) had HCV, and 0.2% (1/499) had HIV. Among the 327 patients with CD, 2.8% (8/288) had HBV, 0.7% (2/273) had HCV, and 0% (0/277) had HIV. One patient with CD had HBV and HCV coinfection. The prevalence of HBV, HCV, and HIV in patients with ITB was 5.9% (4/67), 1.8% (1/57), and 1.2% (1/84), respectively.

Conclusions

The prevalence of HBV, HCV, and HIV in north Indian patients with IBD is similar to the prevalence of these viruses in the general community. Nonetheless, the high risk of flare after immunosuppressive therapy mandates routine screening of patients with IBD for viral markers.

Citations

Citations to this article as recorded by  
  • Managing IBD Patients with Concomitant HIV Infection - a Systematic Review
    Hugo Sousa, Joana Barroso, Raquel Tavares, Joana Torres
    Current Gastroenterology Reports.2024; 26(1): 1.     CrossRef
  • Brucellosis in a patient with Crohn's disease treated with infliximab: A case report
    Mansour Altuwaijri, Nasser Alkhraiji, Mosaab Almasry, Saad Alkhowaiter, Nuha Al Amaar, Ammar Alotaibi
    Arab Journal of Gastroenterology.2024;[Epub]     CrossRef
  • Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis
    Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Sunil Kasturi, Amrit Gopan, Sridhar Sundaram, Aditya Kale
    Intestinal Research.2023; 21(3): 392.     CrossRef
  • Expert consensus on vaccination in patients with inflammatory bowel disease in Japan
    Takashi Ishige, Toshiaki Shimizu, Kenji Watanabe, Katsuhiro Arai, Koichi Kamei, Takahiro Kudo, Reiko Kunisaki, Daisuke Tokuhara, Makoto Naganuma, Tatsuki Mizuochi, Atsuko Murashima, Yuta Inoki, Naomi Iwata, Itaru Iwama, Sachi Koinuma, Hirotaka Shimizu, Ke
    Journal of Gastroenterology.2023; 58(2): 135.     CrossRef
  • Prevalence of viral hepatitis infection in India: A systematic review and meta-analysis
    Dhasarathi Kumar, Roshni M. Peter, Alex Joseph, Kalpana Kosalram, Harpreet Kaur
    Journal of Education and Health Promotion.2023;[Epub]     CrossRef
  • Frequency of hepatitis C virus infection in patients with pediatric inflammatory bowel disease: a cross-sectional study
    Sara Tarek, Ayman E. Eskander, Safa Meshaal, Eman Badr, Asmaa Abd El-Hakeem
    Egyptian Pediatric Association Gazette.2023;[Epub]     CrossRef
  • Pancreatic Disorders in Patients with Inflammatory Bowel Disease
    Marilia L. Montenegro, Juan E. Corral, Frank J. Lukens, Baoan Ji, Paul T. Kröner, Francis A. Farraye, Yan Bi
    Digestive Diseases and Sciences.2022; 67(2): 423.     CrossRef
  • Vaccination strategies for Korean patients with inflammatory bowel disease
    Yoo Jin Lee, Eun Soo Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 920.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Involvement of HHV-4 (Epstein–Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-Analysis
    Luigi Marongiu, Sascha Venturelli, Heike Allgayer
    Cancers.2022; 14(20): 5085.     CrossRef
  • Prevalence of serological markers of hepatitis B in inflammatory bowel disease – Experience from a tertiary care centre in South India
    Amol Prabhakar Patil, Ebby George Simon, Amit Kumar Dutta, Anjilivelil Joseph Joseph, Reuben Thomas Kurien, Sudipta Dhar Chowdhury
    Tropical Doctor.2021; 51(3): 326.     CrossRef
  • Comorbidity before and after a diagnosis of inflammatory bowel disease
    Charles N. Bernstein, Zoann Nugent, Seth Shaffer, Harminder Singh, Ruth Ann Marrie
    Alimentary Pharmacology & Therapeutics.2021; 54(5): 637.     CrossRef
  • ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
    T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N
    Journal of Crohn's and Colitis.2021; 15(6): 879.     CrossRef
  • Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment
    Georgios Axiaris, Evanthia Zampeli, Spyridon Michopoulos, Giorgos Bamias
    World Journal of Gastroenterology.2021; 27(25): 3762.     CrossRef
  • Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
    Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
    The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia
    Eun Soo Kim
    Intestinal Research.2017; 15(1): 5.     CrossRef
  • 6,029 View
  • 53 Download
  • 15 Web of Science
  • 17 Crossref
Close layer
Status of serum vitamin B12 and folate in patients with inflammatory bowel disease in China
Shaozhong Huang, Jiayi Ma, Mingming Zhu, Zhihua Ran
Intest Res 2017;15(1):103-108.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.103
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Inflammatory bowel disease (IBD) primarily involves the intestinal tract and can affect vitamin absorption. This study was designed to assess the prevalence of vitamin B12 and folate deficiencies in patients with IBD, and to identify the risk factors associated with abnormal serum vitamin B12 and folate levels.

Methods

We evaluated the medical records of 195 patients with Crohn's disease (CD) and 62 patients with ulcerative colitis (UC), and selected 118 healthy subjects for the control group.

Results

There were more CD patients with vitamin B12 deficiency than UC patients (14.9% vs. 3.2%, P=0.014) and controls (14.9% vs. 4.2%, P=0.003). The prevalence of folate deficiency was higher in CD patients than in controls (13.3% vs. 3.4%, P=0.004). There were no significant differences in the serum vitamin B12 and folate statuses of the UC and control groups. Patients with prior ileal or ileocolic resection showed a higher prevalence of abnormal vitamin B12 levels than those without prior resection (n=6/16, n=23/179; P=0.018). A disease duration within 5 years was a risk factor of abnormal folate levels in CD patients.

Conclusions

This study showed that vitamin B12 and folate deficiencies were more common in patients with CD than in UC patients and controls. Prior ileal or ileocolonic resection was a risk factor of serum vitamin B12 abnormalities, and a disease duration within 5 years was a risk factor of low serum folate levels in CD patients.

Citations

Citations to this article as recorded by  
  • Fatigue in children and adolescents with inflammatory bowel disease: a cross-sectional study
    Yahui Zuo, Jinjin Cao, Yuanyuan Wang, Wenqian Cai, Mei Li
    Frontiers in Pediatrics.2024;[Epub]     CrossRef
  • Role of micronutrients in inflammatory bowel disease
    Wen-Xuan Song, Zi-Han Yu, Xiang-Feng Ren, Ji-Hua Chen, Xin Chen
    World Chinese Journal of Digestology.2023; 31(17): 711.     CrossRef
  • Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease
    Nojoud Faqerah, Daniel Walker, Konstantinos Gerasimidis
    Alimentary Pharmacology & Therapeutics.2023; 58(10): 984.     CrossRef
  • Group B Vitamins: From Homeostasis to Pathogenesis and Treatment of Multiple Sclerosis
    I. N. Abdurasulova, A. V. Dmitriev
    Успехи физиологических наук.2023; 54(1): 26.     CrossRef
  • An assessment of serum vitamin B12 and folate in patients with Crohn’s disease
    Sabiye Akbulut
    Medicine.2022; 101(50): e31892.     CrossRef
  • A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
    Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
    Endocrinología, Diabetes y Nutrición.2021; 68(1): 17.     CrossRef
  • A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
    Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
    Endocrinología, Diabetes y Nutrición (English ed.).2021; 68(1): 17.     CrossRef
  • Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies
    Jordan J. McGing, Shellie Jean Radford, Susan T. Francis, Sébastien Serres, Paul L. Greenhaff, Gordon W. Moran
    Alimentary Pharmacology & Therapeutics.2021; 54(4): 368.     CrossRef
  • Nutritional supplementation for vitamin B12 and vitamin K2 deficiency following ileostomy or colostomy formation
    David Mantle
    Gastrointestinal Nursing.2020; 18(Sup4): S12.     CrossRef
  • Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases
    Alicja Ewa Ratajczak, Anna Maria Rychter, Agnieszka Zawada, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak
    Nutrients.2020; 12(6): 1702.     CrossRef
  • Methyl-donor supplementation prevents intestinal colonization by Adherent-Invasive E. coli in a mouse model of Crohn’s disease
    Elodie Gimier, Mélissa Chervy, Allison Agus, Adeline Sivignon, Elisabeth Billard, Maud Privat, Sandrine Viala, Régine Minet-Quinard, Anthony Buisson, Emilie Vazeille, Nicolas Barnich, Jérémy Denizot
    Scientific Reports.2020;[Epub]     CrossRef
  • Parkinson’s disease: Are gut microbes involved?
    Yogesh Bhattarai, Purna C. Kashyap
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2020; 319(5): G529.     CrossRef
  • Vitamin D deficiency is associated with disease activity in patients with Crohn’s disease
    Kyoung Ho Ko, You Sun Kim, Bo Kyung Lee, Jong Hyun Choi, Yong Moon Woo, Jin Young Kim, Jeong Seop Moon
    Intestinal Research.2019; 17(1): 70.     CrossRef
  • Metagenomic analysis of microbe-mediated vitamin metabolism in the human gut microbiome
    Promi Das, Parizad Babaei, Jens Nielsen
    BMC Genomics.2019;[Epub]     CrossRef
  • Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases
    M. Nedim Ince, David E. Elliott
    Gastroenterology Clinics of North America.2019; 48(2): 237.     CrossRef
  • 8,045 View
  • 60 Download
  • 13 Web of Science
  • 15 Crossref
Close layer
Determining the optimal surveillance interval after a colonoscopic polypectomy for the Korean population?
Jung Lok Lee, Jae Myung Cha, Hye Min Lee, Jung Won Jeon, Min Seob Kwak, Jin Young Yoon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee, Dong Il Park
Intest Res 2017;15(1):109-117.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.109
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Western surveillance strategies cannot be directly adapted to the Korean population. The aim of this study was to estimate the risk of metachronous neoplasia and the optimal surveillance interval in the Korean population.

Methods

Clinical and pathological data from index colonoscopy performed between June 2006 and July 2008 and who had surveillance colonoscopies up to May 2015 were compared between low- and high-risk adenoma (LRA and HRA) groups. The 3- and 5-year cumulative risk of metachronous colorectal neoplasia in both groups were compared.

Results

Among 895 eligible patients, surveillance colonoscopy was performed in 399 (44.6%). Most (83.3%) patients with LRA had a surveillance colonoscopy within 5 years and 70.2% of patients with HRA had a surveillance colonoscopy within 3 years. The cumulative risk of metachronous advanced adenoma was 3.2% within 5 years in the LRA group and only 1.7% within 3 years in the HRA group. The risk of metachronous neoplasia was similar between the surveillance interval of <5 and ≥5 years in the LRA group; however, it was slightly higher at surveillance interval of ≥3 than <3 years in the HRA group (9.4% vs. 2.4%). In multivariate analysis, age and the ≥3-year surveillance interval were significant independent risk factors for metachronous advanced adenoma (P=0.024 and P=0.030, respectively).

Conclusions

Patients had a surveillance colonoscopy before the recommended guidelines despite a low risk of metachronous neoplasia. However, the risk of metachronous advanced adenoma was increased in elderly patients and those with a ≥3-year surveillance interval.

Citations

Citations to this article as recorded by  
  • Risk of developing metachronous colorectal neoplasia after the resection of proximal versus distal adenomas
    Yoon Suk Jung, Nam Hee Kim, Youngwoo Kim, Dong Il Park
    Digestive and Liver Disease.2022; 54(4): 537.     CrossRef
  • Post-polypectomy surveillance interval and advanced neoplasia detection rates: a multicenter, retrospective cohort study
    Amanda J. Cross, Emma C. Robbins, Kevin Pack, Iain Stenson, Matthew D. Rutter, Andrew M. Veitch, Brian P. Saunders, Stephen W. Duffy, Kate Wooldrage
    Endoscopy.2022; 54(10): 948.     CrossRef
  • Comparison of Risk of Metachronous Advanced Colorectal Neoplasia in Patients with Sporadic Adenomas Aged < 50 Versus ≥ 50 years: A Systematic Review and Meta-Analysis
    Yoon Suk Jung, Jung Ho Park, Chan Hyuk Park
    Journal of Personalized Medicine.2021; 11(2): 120.     CrossRef
  • British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines
    Matthew D Rutter, James East, Colin J Rees, Neil Cripps, James Docherty, Sunil Dolwani, Philip V Kaye, Kevin J Monahan, Marco R Novelli, Andrew Plumb, Brian P Saunders, Siwan Thomas-Gibson, Damian J M Tolan, Sophie Whyte, Stewart Bonnington, Alison Scope,
    Gut.2020; 69(2): 201.     CrossRef
  • Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer
    Eun Ran Kim, Hyuk Nam Kwon, Hoonsik Nam, Jae J. Kim, Sunghyouk Park, Young-Ho Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • A Comparison of the Cumulative Incidences of Metachronous Colorectal Adenoma and Cancer According to the Initial FindingsAmong Colonoscopically Followed-up Patients
    Seiji Kimura, Masanori Tanaka, Shinsaku Fukuda
    Nippon Daicho Komonbyo Gakkai Zasshi.2019; 72(6): 395.     CrossRef
  • Impact of obesity and metabolic abnormalities on the risk of metachronous colorectal neoplasia after polypectomy in men
    Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Journal of Gastroenterology and Hepatology.2019; 34(9): 1504.     CrossRef
  • Risk of developing metachronous advanced colorectal neoplasia after colonoscopic polypectomy in patients aged 30 to 39 and 40 to 49 years
    Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Gastrointestinal Endoscopy.2018; 88(4): 715.     CrossRef
  • Quality is the Key for Emerging Issues of Population-Based Colonoscopy Screening
    Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
    Clinical Endoscopy.2018; 51(1): 50.     CrossRef
  • Histologic discrepancy between endoscopic forceps biopsy and endoscopic mucosal resection specimens of colorectal polyp in actual clinical practice
    Moon Joo Hwang, Kyeong Ok Kim, A Lim Kim, Si Hyung Lee, Byung Ik Jang, Tae Nyeun Kim
    Intestinal Research.2018; 16(3): 475.     CrossRef
  • Quality is the key for emerging issues of population-based colonoscopy screening
    Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
    Intestinal Research.2018; 16(1): 48.     CrossRef
  • 6,326 View
  • 60 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
Intestinal barrier integrity and function in infants with cholestasis
Nagla H. Abu Faddan, Tahra M. K. Sherif, Omnia A. Mohammed, Khalid A. Nasif, Ebtesam M. El Gezawy
Intest Res 2017;15(1):118-123.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.118
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

The safety of the human body is maintained by effective monitoring of the mucosal surface integrity and protection against potentially harmful compounds. This function of the gut called intestinal barrier function can be affected by cholestasis and the absence of bile in the intestinal lumen. We aimed to determine whether the gut barrier integrity is impaired in infants with cholestasis by evaluation of the intestinal fatty acid binding proteins (I-FABP) and ileal bile acid binding protein (I-BABP) as markers of intestinal epithelial cell damage and plasma D-lactate level as a marker of gut wall permeability.

Methods

This case-control study included 53 infants with cholestasis and 29 controls. Serum levels of I-FABP, I-BABP, and D-lactate were measured in all subjects.

Results

Both groups of patients with neonatal hepatitis and biliary atresia showed significantly higher levels of I-FABP and I-BABP than the controls. There were no differences in the serum D-lactate level between the cases and controls. There was no difference between the two groups of patients (I and II) regarding any of the parameters studied. No significant correlations between serum levels of I-FABP, I-BABP, or D-lactate and total or direct bilirubin levels were found in the cholestatic infants.

Conclusions

The intestinal epithelial barrier integrity is breached nearly in all parts of the intestine in infants with cholestasis. Further research is recommended to determine the impact of this finding on the management of these infants. The relationship between physical intestinal barrier damage and its functional failure remains subject for further research.

Citations

Citations to this article as recorded by  
  • Biliary atresia: the role of gut microbiome, and microbial metabolites
    Sansan Feng, Yongkang Cheng, Chuqiao Sheng, Chunfeng Yang, Yumei Li
    Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
  • The association of human milk intake and outcomes in biliary atresia
    Mary Elizabeth M. Tessier, Jeremy M. Schraw, Stacey Beer, Sanjiv Harpavat, M. Kyle Jensen, John C. Magee, Vicky Ng, Michael E. Scheurer, Sarah A. Taylor, Benjamin L. Shneider
    Journal of Pediatric Gastroenterology and Nutrition.2024;[Epub]     CrossRef
  • Data-independent acquisition-based blood proteomics unveils predictive biomarkers for neonatal necrotizing enterocolitis
    Feng Chen, Kezhe Tan, Zhibao Lv, Faling Chen, Weijue Xu, Xiaohui Gong, Li Lu, Hailiang Sun, Qinqin Fu, Wenjun Zhuang
    Analytical and Bioanalytical Chemistry.2024;[Epub]     CrossRef
  • Modulating intestinal barrier function by sphingosine-1-phosphate receptor 1 specific agonist SEW2871 attenuated ANIT-induced cholestatic hepatitis via the gut-liver axis
    Tingting Yang, Lin Li, Jiale Pang, Cai Heng, Chujing Wei, Xue Wang, Ziyin Xia, Xin Huang, Luyong Zhang, Zhenzhou Jiang
    International Immunopharmacology.2023; 125: 111150.     CrossRef
  • Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer
    Chenchen Bi, Geqiong Xiao, Chunyan Liu, Junwei Yan, Jiaqi Chen, Wenzhang Si, Jian Zhang, Zheng Liu
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Noninvasive Biomarkers of Gut Barrier Function in Patients Suffering from Diarrhea Predominant-IBS: An Update
    Michele Linsalata, Giuseppe Riezzo, Caterina Clemente, Benedetta D’Attoma, Francesco Russo, Roberta Rizzo
    Disease Markers.2020; 2020: 1.     CrossRef
  • A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis
    Eleanor A Fallon, Bethany M Biron-Girard, Chun-Shiang Chung, Joanne Lomas-Neira, Daithi S Heffernan, Sean F Monaghan, Alfred Ayala
    Journal of Leukocyte Biology.2018; 103(6): 1151.     CrossRef
  • 5,758 View
  • 59 Download
  • 11 Web of Science
  • 7 Crossref
Close layer
Case Reports
Metronidazole-induced encephalopathy in a patient with Crohn's disease
Jihye Kim, Jaeyoung Chun, Jae Yong Park, Seung Wook Hong, Joo Young Lee, Jin Woo Kang, Seongjun Hwang, Sang-Bae Ko, Jong Pil Im, Joo Sung Kim
Intest Res 2017;15(1):124-129.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.124
AbstractAbstract PDFPubReaderePub

Metronidazole is a widely used antibiotic for the treatment of anaerobic bacterial infections. Metronidazole-induced encephalopathy (MIEP) is a rare but potentially reversible disease. The mechanism of MIEP remains unclear, and differences in the neurotoxic effects of oral versus intravenous (IV) metronidazole administration have not yet been determined. We report the case of a Crohn's disease (CD) patient who experienced encephalopathy immediately after a single IV dose of metronidazole following long-term exposure to the oral form of the drug. The 64-year-old man with intractable CD experienced a sudden change in mental status, aphasia, and muscle weakness after IV administration of metronidazole. He had previously taken metronidazole orally for 13 years and received intermittent IV metronidazole treatments for CD exacerbation. Brain magnetic resonance imaging (MRI) showed high-intensity signals in the bilateral medial thalamus and the midbrain and pontine tegmentum on fluid-attenuated inversion recovery images. After discontinuation of metronidazole, the high-intensity brain MRI signals resolved and the patient's mental status dramatically improved; however, the patient exhibited mild cognitive dysfunction 2 months after the onset of encephalopathy.

Citations

Citations to this article as recorded by  
  • Unveiling the Neurotoxicity of Metronidazole: A Clinical Conundrum
    Gollapudi Hithesh, Swathy Moorthy, Lakshmi M, Emmanuel Bhaskar
    Cureus.2024;[Epub]     CrossRef
  • Diffuse subcortical white matter restriction: An uncommon finding on metronidazole toxicity
    Mehri Salari, Masoud Etemadifar, Helia Ashourizadeh
    The Neuroradiology Journal.2023; 36(1): 119.     CrossRef
  • MRI Findings and Topographic Distribution of Lesions in Metronidazole-Induced Encephalopathy
    Ambreen Fatima, Sachin Khanduri, Sadaf Sultana, Surbhi ., Saim A Siddiqui, Ashkrit Gupta, Vaibhav Pathak, Mohsin Mulani, Salma Khan, Tanya Bansal
    Cureus.2022;[Epub]     CrossRef
  • The Influence of Omeprazole on the Dissolution Processes of pH-Dependent Magnetic Tablets Assessed by Pharmacomagnetography
    Guilherme A. Soares, Deivid W. Pires, Leonardo A. Pinto, Gustavo S. Rodrigues, André G. Prospero, Gabriel G. A. Biasotti, Gabriela N. Bittencourt, Erick G. Stoppa, Luciana A. Corá, Ricardo B. Oliveira, José R. A. Miranda
    Pharmaceutics.2021; 13(8): 1274.     CrossRef
  • Metronidazole-induced encephalopathy: a systematic review
    Caspar Godthaab Sørensen, William Kristian Karlsson, Faisal Mohammad Amin, Mette Lindelof
    Journal of Neurology.2020; 267(1): 1.     CrossRef
  • Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment
    Zhigang Liu, Xiaoshuang Dai, Hongbo Zhang, Renjie Shi, Yan Hui, Xin Jin, Wentong Zhang, Luanfeng Wang, Qianxu Wang, Danna Wang, Jia Wang, Xintong Tan, Bo Ren, Xiaoning Liu, Tong Zhao, Jiamin Wang, Junru Pan, Tian Yuan, Chuanqi Chu, Lei Lan, Fei Yin, Enriq
    Nature Communications.2020;[Epub]     CrossRef
  • Anti-protozoal Activity of Conifer Green Needle Complex against Trichomonas vaginalis
    Lidia B. Kulyashova, Natalia Roschina, Tamara V. Nikitina, Vagif S. Soultanov
    Natural Product Communications.2019;[Epub]     CrossRef
  • Reversible metronidazole-induced neurotoxicity after 10 weeks of therapy
    Wafa AlDhaleei, Ayesha AlMarzooqi, Nouran Gaber
    BMJ Case Reports.2018; : bcr-2017-223463.     CrossRef
  • 7,111 View
  • 80 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Capsule retention caused by duodenal metastases from primary appendiceal adenocarcinoma
Jen-Wei Chou, Ken-Sheng Cheng
Intest Res 2017;15(1):130-132.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.130
AbstractAbstract PDFPubReaderePub

Metastatic small bowel cancers are extremely rare in clinical practice. Primary appendiceal adenocarcinoma with gastrointestinal metastasis is seldom reported in the literature. Here, we describe the case of an 80-year-old male patient with primary appendiceal adenocarcinoma, who presented to China Medical University Hospital with mid-gastrointestinal tract bleeding. Capsule endoscopy revealed stenotic bowel lumen, but the capsule was retained in the distal duodenum. Double-balloon enteroscopy demonstrated erosive and erythematous mucosa in the region of capsule retention. The retained capsule was retrieved successfully by using an electrosurgical snare. Histological examination and immunohistochemical staining of the biopsy specimen from the duodenal lesion strongly supported the diagnosis of metastatic appendiceal adenocarcinoma.

  • 4,502 View
  • 34 Download
Close layer
Crohn's disease with ankylosing spondylitis in an adolescent patient who had undergone long ileo-colonic anastomosis for Hirschsprung's disease as an infant
Ha Yeon Kim, Tae Wook Kim
Intest Res 2017;15(1):133-137.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.133
AbstractAbstract PDFPubReaderePub

Crohn's disease (CD) is a chronic, idiopathic, inflammatory disorder of the gastrointestinal tract. In rare cases, CD has been associated with Hirschsprung's disease (HD); however, the underlying pathophysiology of this and other comorbidities is not yet fully understood. In this report, we describe the case of a 17-year-old patient who was diagnosed with both CD and ankylosing spondylitis (AS), having undergone a long ileo-colonic anastomosis to treat HD at 12 months of age. To our knowledge, this is the first documented case of CD combined with AS in a patient with HD.

Citations

Citations to this article as recorded by  
  • Crohn’s disease in patients with Hirschsprung disease and Hirschsprung-associated enterocolitis: A review
    Victoria A. Glushkova, Aleksey V. Podkamenev, Tatyana V. Gabrusskaya
    Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care.2024; 14(1): 97.     CrossRef
  • Transcriptome profiling of intact bowel wall reveals that PDE1A and SEMA3D are possible markers with roles in enteric smooth muscle apoptosis, proliferative disorders, and dysautonomia in Crohn’s disease
    Yun Yang, Lin Xia, Wenming Yang, Ziqiang Wang, Wenjian Meng, Mingming Zhang, Qin Ma, Junhe Gou, Junjian Wang, Ye Shu, Xiaoting Wu
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • A unicentric cross-sectional observational study on chronic intestinal inflammation in total colonic aganglionosis: beware of an underestimated condition
    M Erculiani, F Poluzzi, G Mottadelli, E Felici, Novi ML, M Caraccia, A Grandi, S Casella, L Giacometti, G Montobbio, I Ceccherini, E Di Marco, C Bonaretti, R Biassoni, M Squillario, A Pietrantoni, V Villanacci, A Pini Prato
    Orphanet Journal of Rare Diseases.2023;[Epub]     CrossRef
  • Clinical characteristics and validation of diagnosis in individuals with Hirschsprung disease and inflammatory bowel disease
    Anna Löf Granström, Jonas F Ludvigsson, Tomas Wester
    Journal of Pediatric Surgery.2021; 56(10): 1799.     CrossRef
  • Crohn-Like Colitis in a Young Boy With Hirschsprung Disease
    Alessandra Verde, Angelina Grammegna, Emma Petrone, Augusto Mastrominico, Daniele De Brasi, Claudia Mandato, Giusy Ranucci, Maria Simona Sabbatino, Michelina Sibilio, Paolo Quitadamo
    Inflammatory Bowel Diseases.2021; 27(9): e112.     CrossRef
  • Inflammatory bowel disease in patients with Hirschsprung’s disease: a systematic review and meta-analysis
    H. Nakamura, T. Lim, P. Puri
    Pediatric Surgery International.2018; 34(2): 149.     CrossRef
  • Increased Risk of Inflammatory Bowel Disease in a Population‐based Cohort Study of Patients With Hirschsprung Disease
    Anna Löf Granström, Leila Amin, Henrik Arnell, Tomas Wester
    Journal of Pediatric Gastroenterology and Nutrition.2018; 66(3): 398.     CrossRef
  • 5,805 View
  • 68 Download
  • 6 Web of Science
  • 7 Crossref
Close layer
Brief Communication
Pivot to Asia: inflammatory bowel disease burden
Prashant Singh, Ashwin Ananthakrishnan, Vineet Ahuja
Intest Res 2017;15(1):138-141.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.138
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • IBD Card: Promoting continuity in care for patients with inflammatory bowel disease
    Harshavardhan Telaprolu, Anupam K. Singh, Vishal Sharma, Usha Dutta
    Indian Journal of Gastroenterology.2024; 43(1): 7.     CrossRef
  • Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
    Mukesh Kumar Ranjan, Peeyush Kumar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Sandeep K Mundhra, Rithvik Golla, Shubi Virmani, Raju Sharma, Peush Sahni, Prasenjit Das, Mani Kalaivani, Ashish Datt Upadhyay, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Journal of Crohn's and Colitis.2024; 18(2): 192.     CrossRef
  • Perianal fistulizing Crohn’s disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies
    Jalpa Devi, David H. Ballard, Tina Aswani-Omprakash, Alyssa M. Parian, Parakkal Deepak
    Indian Journal of Gastroenterology.2024; 43(1): 48.     CrossRef
  • Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB
    Renata de Sá Brito Fróes, Adriana Ribas Andrade, Mikaell Alexandre Gouvea Faria, Heitor Siffert Pereira de Souza, Rogério Serafim Parra, Cyrla Zaltman, Carlos Henrique Marques dos Santos, Mauro Bafutto, Abel Botelho Quaresma, Genoile Oliveira Santana, Raf
    Scientific Reports.2024;[Epub]     CrossRef
  • Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening
    Suprabhat Giri, Sukanya Bhrugumalla, Akash Shukla, Sagar Gangadhar, Srujan Reddy, Sumaswi Angadi, Leela Shinde, Aditya Kale
    Arab Journal of Gastroenterology.2024;[Epub]     CrossRef
  • Challenges in IBD Research 2024: Environmental Triggers
    Ashwin N Ananthakrishnan, Kostantinos Gerasimidis, Shuk-Mei Ho, Emeran Mayer, Jennifer Pollock, Shefali Soni, Gary D Wu, Jalil Benyacoub, Basmah Ali, Alex Favreau, Denise Elsbree Smith, Ji-eun Oh, Caren Heller, Andres Hurtado-Lorenzo, Alan Moss, Ken Croit
    Inflammatory Bowel Diseases.2024; 30(Supplement): S19.     CrossRef
  • Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatment
    Aaron T. Kao, Christian V. Cabanlong, Kendra Padilla, Xiang Xue
    Acta Pharmaceutica Sinica B.2024; 14(9): 3785.     CrossRef
  • Analysis of the effect of hypusination in myeloid cells on colitis and colitis-associated cancer.
    Alain P. Gobert, Jordan Finley, Mohammad Asim, Daniel P. Barry, Margaret M. Allaman, Caroline V. Hawkins, Kamery J. Williams, Alberto G. Delagado, Raghavendra G. Mirmira, Shilin Zhao, M. Blanca Piazuelo, M. Kay Washington, Lori A. Coburn, Keith T. Wilson
    Heliyon.2024; : e33838.     CrossRef
  • Debate on the relationship between Helicobacter pylori infection and inflammatory bowel disease: a bibliometric analysis
    Ziye Wang, Shiqing Zhao, Xiaotian Zhong, Yi Su, Yahan Song, Jun Li, Yanyan Shi
    Frontiers in Microbiology.2024;[Epub]     CrossRef
  • Ileocolic Enteroenteric Fistula in Small Bowel Obstruction With Cecum Perforation in the Pediatric Age Group: A Case Report of a Rare Complication
    Survesh k Gupta, Umesh K Gupta, Rafey A Rahman, Anil Kumar
    Cureus.2024;[Epub]     CrossRef
  • Granulomatous inflammation is less common in delayed-onset Crohn's disease
    Madeline Vithya Barnaba Durairaj, Rajeeb Jaleel, Anna B Pulimood
    Tropical Doctor.2023; 53(1): 113.     CrossRef
  • High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India
    Bhaskar Kante, Sudheer Kumar Vuyyuru, Ritu Gupta, Tanima Dwivedi, Peeyush Kumar, Sandeep Mundhra, Rithvik Golla, Shubi Virmani, Mahak Verma, Govind Makharia, Vineet Ahuja, Saurabh Kedia
    Indian Journal of Gastroenterology.2023; 42(1): 70.     CrossRef
  • Interferon-gamma release assay has poor diagnostic accuracy in differentiating intestinal tuberculosis from Crohn’s disease in tuberculosis endemic areas
    Karan Sachdeva, Peeyush Kumar, Bhaskar Kante, Sudheer K. Vuyyuru, Srikant Mohta, Mukesh K. Ranjan, Mukesh K. Singh, Mahak Verma, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Intestinal Research.2023; 21(2): 226.     CrossRef
  • Hypusination Maintains Intestinal Homeostasis and Prevents Colitis and Carcinogenesis by Enhancing Aldehyde Detoxification
    Alain P. Gobert, Thaddeus M. Smith, Yvonne L. Latour, Mohammad Asim, Daniel P. Barry, Margaret M. Allaman, Kamery J. Williams, Kara M. McNamara, Alberto G. Delgado, Sarah P. Short, Raghavendra G. Mirmira, Kristie L. Rose, Kevin L. Schey, Irene Zagol-Ikapi
    Gastroenterology.2023; 165(3): 656.     CrossRef
  • Differentiating gastrointestinal tuberculosis and Crohn's disease- a comprehensive review
    Arup Choudhury, Jasdeep Dhillon, Aravind Sekar, Pankaj Gupta, Harjeet Singh, Vishal Sharma
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Colon-Adhering Delivery System with Inflammation Responsiveness for Localized Therapy of Experimental Colitis
    Ajay Kumar, Kanika, Vibhu Kumar, Anas Ahmad, Rakesh Kumar Mishra, Ahmed Nadeem, Nahid Siddiqui, Md Meraj Ansari, Syed Shadab Raza, Kanthi Kiran Kondepudi, Rehan Khan
    ACS Biomaterials Science & Engineering.2023; 9(8): 4781.     CrossRef
  • Diagnosis of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Han Hee Lee, Jae Jun Park, Bo-In Lee, Ida Hilmi, Jose Sollano, Zhi Hua Ran
    Intestinal Research.2023; 21(3): 328.     CrossRef
  • Synthesis of some Curcumin derivatives of Non-Steroidal Anti-Inflammatory (NSAIDs) Prodrugs for Treatment of Inflammatory Bowel Diseases
    Yogendra Kumar, Nidhi Agrawal, Meenakshi Jaiswal
    Research Journal of Pharmacy and Technology.2023; : 2733.     CrossRef
  • Inflammatory Bowel Disease and X (Formerly Twitter) Influencers: Who Are They and What Do They Say?
    Ayushi Garg, Aalam Sohal, Shivam Kalra, Carol Singh, Ishandeep Singh, Jasneet Grewal, Rohin Kansal, Kashish Malhotra, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Ajit Sood, Ashvind Bawa
    Cureus.2023;[Epub]     CrossRef
  • Protective Role of Spermidine in Colitis and Colon Carcinogenesis
    Alain P. Gobert, Yvonne L. Latour, Mohammad Asim, Daniel P. Barry, Margaret M. Allaman, Jordan L. Finley, Thaddeus M. Smith, Kara M. McNamara, Kshipra Singh, Johanna C. Sierra, Alberto G. Delgado, Paula B. Luis, Claus Schneider, M. Kay Washington, M. Blan
    Gastroenterology.2022; 162(3): 813.     CrossRef
  • Geosocial Features and Loss of Biodiversity Underlie Variable Rates of Inflammatory Bowel Disease in a Large Developing Country: A Population-Based Study
    Andre da Luz Moreira, Luiz Felipe de Campos Lobato, Jessica Pronestino de Lima Moreira, Ronir Raggio Luiz, Celeste Elia, Claudio Fiocchi, Heitor Siffert Pereira de Souza
    Inflammatory Bowel Diseases.2022; 28(11): 1696.     CrossRef
  • Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region
    Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit
    Alimentary Pharmacology & Therapeutics.2022; 55(11): 1431.     CrossRef
  • Differential colitis susceptibility of Th1- and Th2-biased mice: A multi-omics approach
    Sohini Mukhopadhyay, Subha Saha, Subhayan Chakraborty, Punit Prasad, Arindam Ghosh, Palok Aich, Lili Chen
    PLOS ONE.2022; 17(3): e0264400.     CrossRef
  • Genome-wide DNA methylation profiling in differentiating Crohn’s disease from intestinal tuberculosis
    Hao Wu, Hongchun Liu, Haining Liu, Yanjie Chen, Taotao Liu, Xizhong Shen, Lili Liu
    Genes & Genomics.2022; 44(5): 603.     CrossRef
  • Addition of computed tomography chest increases the diagnosis rate in patients with suspected intestinal tuberculosis
    Saurabh Kedia, Raju Sharma, Sudheer Kumar Vuyyuru, Deepak Madhu, Pabitra Sahu, Bhaskar Kante, Prasenjit Das, Ankur Goyal, Karan Madan, Govind Makharia, Vineet Ahuja
    Intestinal Research.2022; 20(2): 184.     CrossRef
  • Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
    Sang Hyoung Park
    Intestinal Research.2022; 20(2): 159.     CrossRef
  • Minimal risk of lymphoma and non‐melanoma skin cancer despite long‐term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India
    Mukesh Kumar Ranjan, Bhaskar Kante, Sudheer Kumar Vuyyuru, Peeyush Kumar, Sandeep K Mundhra, Rithvik Golla, Raju Sharma, Peush Sahni, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1544.     CrossRef
  • Does the road to primary prevention of inflammatory bowel disease start from childhood?
    Saurabh Kedia, Vineet Ahuja
    JGH Open.2022; 6(6): 365.     CrossRef
  • Applying logistic LASSO regression for the diagnosis of atypical Crohn's disease
    Ying Li, Fanggen Lu, Yani Yin
    Scientific Reports.2022;[Epub]     CrossRef
  • Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial
    Saurabh Kedia, Shubi Virmani, Sudheer K Vuyyuru, Peeyush Kumar, Bhaskar Kante, Pabitra Sahu, Kanav Kaushal, Mariyam Farooqui, Mukesh Singh, Mahak Verma, Aditya Bajaj, Manasvini Markandey, Karan Sachdeva, Prasenjit Das, Govind K Makharia, Vineet Ahuja
    Gut.2022; 71(12): 2401.     CrossRef
  • Thromboembolism is associated with poor prognosis and high mortality in patients with inflammatory bowel disease: A case–control study
    Yadukrishna S., Saurabh Kedia, Varun Teja, Sudheer Kumar Vuyyuru, Nidhi Yadav, Pabitra Sahu, Saransh Jain, Dawesh P. Yadav, Sawan Bopanna, Venigalla Pratap Mouli, Deepak Madhu, Raju Sharma, Prasenjit Das, Govind Makharia, Vineet Ahuja
    Indian Journal of Gastroenterology.2022;[Epub]     CrossRef
  • INCIDENCE OF INFLAMMATORY BOWEL DISEASE: A SINGLE CENTRE RETROSPECTIVE STUDY
    Ajay Kumar OLI, Rohit N MAIDUR, Preetham S HURKADLI, Anita P JAVALGI, Palaksha Kanive JAVAREGOWDA, Mallikarjun GONI
    Arquivos de Gastroenterologia.2022; 59(3): 345.     CrossRef
  • Development and Validation of a Smartphone Application for Telenutrition in Patients with Inflammatory Bowel Disease
    Arti Gupta, Namrata Singh, Divya Madan, Mariyam Farooqui, Neha Singh, David Mathew Thomas, Bhaskar Kante, Mukesh Singh, Shubi Virmani, Mehak Verma, Aditya Bajaj, Manasvini Markandey, Peeyush Kumar, Sudheer Kumar Vuyyuru, Pabitra Sahu, Nitika Monga, Govind
    Diagnostics.2022; 12(10): 2482.     CrossRef
  • Protective Effect of Perilla Oil Against Dextran Sodium Sulfate-Induced Colitis in Mice Challenged with a High-Fat Diet
    Shalom Sara Thomas, Youn-Soo Cha, Kyung-Ah Kim
    Journal of Medicinal Food.2022; 25(11): 1021.     CrossRef
  • Difficulties in differential diagnosis tuberculosis and Crohn's disease. Case report
    Oleg V. Knyazev, Anna V. Kagramanova, Nina A. Fadeeva, Irina G. Pelipas, Albina A. Lishchinskaya, Maria Iu. Zvyaglova, Asfold I. Parfenov
    Consilium Medicum.2022; 24(5): 287.     CrossRef
  • Development and Validation of a Digital Health Platform (IBD NutriCare) for Telenutrition in Patients With Inflammatory Bowel Disease
    Arti Gupta, Namrata Singh, Bhaskar Kante, Divya Madan, Mariyam Farooqui, Neha Singh, Mukesh Singh, Shubi Virmani, Mehak Verma, Aditya Bajaj, Manasvini Markandey, Peeyush Kumar, Sudheer Kumar Vuyyuru, Pabitra Sahu, Govind Makharia, Saurabh Kedia, Vineet Ah
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Inflammatory bowel disease in India: challenges and opportunities
    Alice Snell, Jonathan Segal, Jimmy Limdi, Rupa Banerjee
    Frontline Gastroenterology.2021; 12(5): 390.     CrossRef
  • Incidence and Prevalence of Inflammatory Bowel Disease across Asia
    Jihye Park, Jae Hee Cheon
    Yonsei Medical Journal.2021; 62(2): 99.     CrossRef
  • The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
    Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
    Intestinal Research.2021; 19(1): 62.     CrossRef
  • Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn’s disease
    Gurasis Boparai, Saurabh Kedia, Devasenathipathy Kandasamy, Raju Sharma, Kumble Seetharama Madhusudhan, Nihar Ranjan Dash, Pabitra Sahu, Sujoy Pal, Peush Sahni, Rajesh Panwar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Davesh P. Yadav, Venigalla Pratap Mouli,
    European Journal of Clinical Nutrition.2021; 75(10): 1491.     CrossRef
  • Intestinal tuberculosis or Crohn's disease: Illusion or delusion or allusion
    Saurabh Kedia, Vineet Ahuja
    JGH Open.2021; 5(2): 177.     CrossRef
  • Deep‐learning system for real‐time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis
    Jung Min Kim, Jun Gu Kang, Sungwon Kim, Jae Hee Cheon
    Journal of Gastroenterology and Hepatology.2021; 36(8): 2141.     CrossRef
  • Increased Interleukin-10 Expression by the Inhibition of Ca2+-Activated K+ Channel KCa3.1 in CD4+CD25+ Regulatory T Cells in the Recovery Phase in an Inflammatory Bowel Disease Mouse Model
    Susumu Ohya, Miki Matsui, Junko Kajikuri, Kyoko Endo, Hiroaki Kito
    The Journal of Pharmacology and Experimental Therapeutics.2021; 377(1): 75.     CrossRef
  • The Impact of Migration on the Gut Metagenome of South Asian Canadians
    Julia K. Copeland, Gary Chao, Shelley Vanderhout, Erica Acton, Pauline W. Wang, Eric I. Benchimol, Ahmed El-Sohemy, Ken Croitoru, Jennifer L. Gommerman, David S. Guttman
    Gut Microbes.2021;[Epub]     CrossRef
  • Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
    Ajit Sood, Kirandeep Kaur, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Sarit Sharma, Amarender Singh Puri, Bhabhadev Goswami, Devendra Desai, C. Ganesh Pai, Kiran Peddi, Mathew Philip, Rakesh Kochhar, Sandeep Nijhawan, Shobna Bhatia, N. Sridhara Rao
    Intestinal Research.2021; 19(2): 206.     CrossRef
  • Prospective validation of CD4+CD25+FOXP3+ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease
    Ritika Rampal, Saurabh Kedia, Mohamad Nahidul Wari, Deepak Madhu, Amit Kumar Singh, Veena Tiwari, V. Pratap Mouli, Srikant Mohta, Govind Makharia, Vineet Ahuja
    Intestinal Research.2021; 19(2): 232.     CrossRef
  • A report of nonexistence of the non-Helicobacter pylori Helicobacter species in Iranian patients suffering from inflammatory bowel disease
    Samira Pirmanesh, Nasrin Mirzaei, Masoumeh Azimirad, Abbas Yadegar, John Y. Kao, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali
    Folia Microbiologica.2021; 66(5): 751.     CrossRef
  • Inflammatory bowel diseases in Tamil Nadu: A survey of demographics, clinical profile, and practices
    Rohan V Yewale, Kartik Natarajan, Jeyaraj Ubal Dhus, Sarojini Ashok Parameswaran, Kallipatti Ramaswamy Palaniswamy, Doraisamy Babu Vinish, Aravindh Somasundaram, Arulraj Ramakrishnan, Sibithooran Karmegam, Ramaswamy Saraswathy Arun, Ujjani Shankaraiah Man
    JGH Open.2021; 5(11): 1306.     CrossRef
  • Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Jooyoung Lee, Jong Pil Im, Kyungdo Han, Jihye Kim, Hyun Jung Lee, Jaeyoung Chun, Joo Sung Kim
    Gut and Liver.2020; 14(1): 89.     CrossRef
  • Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century
    Ashwin N. Ananthakrishnan, Gilaad G. Kaplan, Siew C. Ng
    Clinical Gastroenterology and Hepatology.2020; 18(6): 1252.     CrossRef
  • Inflammatory Bowel Diseases in South Asian Patients: Underappreciated and Understudied
    Bharati Kochar
    Inflammatory Bowel Diseases.2020;[Epub]     CrossRef
  • Dairy Propionibacterium freudenreichii ameliorates acute colitis by stimulating MUC2 expression in intestinal goblet cell in a DSS-induced colitis rat model
    Seongho Ma, Jiah Yeom, Young-Hee Lim
    Scientific Reports.2020;[Epub]     CrossRef
  • Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India
    Pabitra Sahu, Sudheer K. Vuyyuru, Bhaskar Kante, Ashish Agarwal, Raju Sharma, Prasenjit Das, Rajesh Panwar, Saransh Jain, Sawan Bopanna, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Indian Journal of Gastroenterology.2020; 39(4): 388.     CrossRef
  • Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
    Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kir
    Intestinal Research.2020; 18(4): 355.     CrossRef
  • Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis
    Murtaza M. Tambuwala, Mohammed N. Khan, Paul Thompson, Paul A. McCarron
    Drug Delivery and Translational Research.2019; 9(1): 14.     CrossRef
  • Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
    Nagesh Kamat, Saurabh Kedia, Uday C. Ghoshal, Abhimanyu Nehra, Govind Makharia, Ajit Sood, Vandana Midha, Varun Gupta, Gourdas Choudhuri, Vineet Ahuja
    Indian Journal of Gastroenterology.2019; 38(1): 44.     CrossRef
  • Differentiating Crohn’s disease from intestinal tuberculosis
    Saurabh Kedia, Prasenjit Das, Kumble Seetharama Madhusudhan, Siddhartha Dattagupta, Raju Sharma, Peush Sahni, Govind Makharia, Vineet Ahuja
    World Journal of Gastroenterology.2019; 25(4): 418.     CrossRef
  • Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease
    Sanjeevani K Tomar, Saurabh Kedia, Namrata Singh, Ashish D Upadhyay, Nagesh Kamat, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja
    JGH Open.2019; 3(4): 302.     CrossRef
  • Dietary Arginine Regulates Severity of Experimental Colitis and Affects the Colonic Microbiome
    Kshipra Singh, Alain P. Gobert, Lori A. Coburn, Daniel P. Barry, Margaret Allaman, Mohammad Asim, Paula B. Luis, Claus Schneider, Ginger L. Milne, Helen H. Boone, Meghan H. Shilts, M. Kay Washington, Suman R. Das, M. Blanca Piazuelo, Keith T. Wilson
    Frontiers in Cellular and Infection Microbiology.2019;[Epub]     CrossRef
  • Impaired neurocognitive and psychomotor performance in patients with inflammatory bowel disease
    Ivana Tadin Hadjina, Piero Marin Zivkovic, Andrija Matetic, Doris Rusic, Marino Vilovic, Diana Bajo, Zeljko Puljiz, Ante Tonkic, Josko Bozic
    Scientific Reports.2019;[Epub]     CrossRef
  • All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance
    Grace B. Hatton, Christine M. Madla, Sarit C. Rabbie, Abdul W. Basit
    International Journal of Pharmaceutics.2018; 548(1): 408.     CrossRef
  • Colonic Crohn’s Disease Is Associated with Less Aggressive Disease Course Than Ileal or Ileocolonic Disease
    Umang Arora, Saurabh Kedia, Prerna Garg, Sawan Bopanna, Saransh Jain, Dawesh P. Yadav, Sandeep Goyal, Vipin Gupta, Peush Sahni, Sujoy Pal, Nihar Ranjan Dash, Kumble Seetharama Madhusudhan, Raju Sharma, Govind Makharia, Vineet Ahuja
    Digestive Diseases and Sciences.2018; 63(6): 1592.     CrossRef
  • Distinct Immunomodulatory Effects of Spermine Oxidase in Colitis Induced by Epithelial Injury or Infection
    Alain P. Gobert, Nicole T. Al-Greene, Kshipra Singh, Lori A. Coburn, Johanna C. Sierra, Thomas G. Verriere, Paula B. Luis, Claus Schneider, Mohammad Asim, Margaret M. Allaman, Daniel P. Barry, John L. Cleveland, Christina E. Destefano Shields, Robert A. C
    Frontiers in Immunology.2018;[Epub]     CrossRef
  • Combination of increased visceral fat and long segment involvement: Development and validation of an updated imaging marker for differentiating Crohn's disease from intestinal tuberculosis
    Saurabh Kedia, Kumble S Madhusudhan, Raju Sharma, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Prasenjit Das, Siddhartha Dattagupta, Govind Makharia, Vineet Ahuja
    Journal of Gastroenterology and Hepatology.2018; 33(6): 1234.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • Is the emergence of inflammatory bowel disease a prime example of “the third epidemiological transition”?
    Saurabh Kedia, Vineet Ahuja
    Indian Journal of Gastroenterology.2018; 37(3): 183.     CrossRef
  • The importance of immunization in immune-mediated inflammatory disease cannot be overstated
    Sang Hyoung Park
    Intestinal Research.2018; 16(3): 325.     CrossRef
  • Management of inflammatory bowel disease in older persons: evolving paradigms
    Saurabh Kedia, Jimmy K. Limdi, Vineet Ahuja
    Intestinal Research.2018; 16(2): 194.     CrossRef
  • Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study
    Saransh Jain, Saurabh Kedia, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Peush Sahni, Sujoy Pal, Nihar Ranjan Dash, Govind Makharia, Simon P. L. Travis, Vineet Ahuja
    Intestinal Research.2018; 16(1): 69.     CrossRef
  • Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
    Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
    Current Infectious Disease Reports.2018;[Epub]     CrossRef
  • High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
    Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
    Intestinal Research.2018; 16(4): 588.     CrossRef
  • Genetics of ulcerative colitis: putting into perspective the incremental gains from Indian studies
    Garima Juyal, Ajit Sood, Vandana Midha, B. K. Thelma
    Journal of Genetics.2018; 97(5): 1493.     CrossRef
  • Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Won Ho Kim, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2017; 62(8): 2102.     CrossRef
  • Body Composition in Crohn’s Disease and Ulcerative Colitis: Correlation with Disease Severity and Duration
    Dawesh P. Yadav, Saurabh Kedia, Kumble Seetharama Madhusudhan, Sawan Bopanna, Sandeep Goyal, Saransh Jain, Naval K. Vikram, Raju Sharma, Govind K. Makharia, Vineet Ahuja
    Canadian Journal of Gastroenterology and Hepatology.2017; 2017: 1.     CrossRef
  • Impact of dietary beliefs and practices on patients with inflammatory bowel disease: An observational study from India
    Sanjeevani K Tomar, Saurabh Kedia, Ashish D Upadhyay, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja, Namrata Singh
    JGH Open.2017; 1(1): 15.     CrossRef
  • 9,259 View
  • 106 Download
  • 70 Web of Science
  • 75 Crossref
Close layer
Images of the Issue
Polypoid lesions at the anal canal: what do they hint?
Shu Chen Wei, Been Ren Lin, Chia Tung Shun, Jau Min Wong
Intest Res 2017;15(1):142-143.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.142
PDFPubReaderePub
  • 4,911 View
  • 41 Download
Close layer

Intest Res : Intestinal Research
Close layer
TOP